Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Jumia Technologies AG - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.81 (market cap $39.89B), while Jumia Technologies AG - ADR trades at $6.97 (market cap $868.21M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 45.9× Jumia Technologies AG - ADR's market cap, and Jumia Technologies AG - ADR is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | JMIA | |
|---|---|---|
Market Cap | $39.89B | $868.21M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $14.60 |
52-Week Low | $278.09 | $4.26 |
Enterprise Value | $38.15B | $815.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
JMIA trades at $7.01, up 1.45% today, amid a bearish technical signal and mixed earnings. The company reported Q1 2026 revenue growth of 39% but missed EPS expectations, with a net income margin of -30.79%. Cash flow improved with a net inflow of $21.31M in 2025, and management reaffirmed a 2027 profitability target. The stock shows neutral oscillators but bearish moving averages, with support and resistance clustered around $7.
The outlook hinges on JMIA's path to profitability by 2027, supported by expansion initiatives and partnerships like Starlink. Risks include persistent losses, competitive pressures in African e-commerce, and macroeconomic headwinds. Analyst consensus is strongly bullish with 71% buy ratings, but investors must weigh growth potential against execution risks and current negative returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
